|

TRUST-ACE - Anticancer-treatment Cardiotoxicity Identification by Echocardiography

RECRUITINGN/ASponsored by Norwegian University of Science and Technology
Actively Recruiting
PhaseN/A
SponsorNorwegian University of Science and Technology
Started2024-03-08
Est. completion2026-12-31
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06310330

Summary

TRUST-ACE will compare a simplified echocardiographic protocol focusing on ventricular function with the guideline recommended comprehensive echocardiographic examination using a randomised design in follow-up of breast-cancer patients with respect to identification of cancer treatment related cardiac dysfunction (CTRCD). Secondly, the study will evaluate whether novel tools used to improve standardization of recordings as well as automated measurements of central measurements, e.g. ejection fraction (EF) and global longitudinal strain (GLS) can improve the precision of echocardiography in daily clinical practice.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Breast cancer and referral for follow-up to identify potential CTRCD

Exclusion Criteria:

* Not willing or able to consent

Conditions4

Breast CancerBreast Neoplasm Malignant PrimaryCancerHeart Disease

Browse More Trials

Cancer trialsHeart Disease trialsBreast Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.